Drugs / Veligrotug
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01233895 | Sep 2006 → Sep 2008 | plasma cell myeloma | Sanofi | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00791544 | Nov 2008 → Nov 2009 | liver cancer | Sanofi | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00774878 | Oct 2008 → Nov 2010 | breast neoplasm | Sanofi | Terminated | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT06179875 | Jan 2024 → Apr 2025 | endocrine exophthalmos | Viridian Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT06021054 | Nov 2023 → Nov 2024 | endocrine exophthalmos | Viridian Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT05176639 | Dec 2021 → Jul 2024 | endocrine exophthalmos | Viridian Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT07832136 | Sep 2026 → Apr 2027 expected | endocrine exophthalmos | Viridian Therapeutics, Inc. | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2008-06-01 | AbbVie | Results ImmunoGen, Inc. Announces Clinical Findings Reported at ASCO with Targeted Anticancer Compounds IMGN242 and AVE1642 abbvie.com ↗
AVE1642 has been found to demonstrate substantial and sustained biological effect when used in combination with docetaxel in the treatment of solid tumors. |
| 2007-12-09 | AbbVie | Results ImmunoGen, Inc. Announces Encouraging Clinical Findings Reported at ASH Annual Meeting for TAP Compound AVE9633 abbvie.com ↗
In addition to the AVE9633 and SAR3419 findings presented, our collaborator sanofi-aventis also reported very encouraging clinical data on the naked antibody, AVE1642, that we initially developed and now is in broad development by them. |
| 2007-12-08 | AbbVie | Results ImmunoGen, Inc. Announces Encouraging Clinical Findings Reported at ASH Annual Meeting with Targeted Anticancer Compounds IMGN901 (HuN901-DM1) and AVE1642 abbvie.com ↗
AVE1642 was successfully evaluated as monotherapy for multiple myeloma in its first Phase I study and is now being tested in combination with Velcade ® (bortezomib) (abstract #1166). |
All press releases naming this drug 5 releases
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | veligrotug | “This is a clinical trial to evaluate the safety and efficacy of veligrotug (LUMVOA™) in participants with moderate to severe TED who previously received and responded to an...” NCT07832136 ↗3“The investigational drug, veligrotug (VRDN-001), is a monoclonal antibody” NCT05176639 ↗ |
| Known as | AVE1642 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01233895 ↗ |
| Known as | LUMVOA | “This is a clinical trial to evaluate the safety and efficacy of veligrotug (LUMVOA™) in participants with moderate to severe TED who previously received and responded to an...” NCT07832136 ↗ |
| Known as | VRDN-001 | “Veligrotug (VRDN-001) is a humanized monoclonal antibody directed against the IGF-1 receptor” NCT06021054 ↗1“The investigational drug, veligrotug (VRDN-001), is a monoclonal antibody” NCT05176639 ↗ |
| Action | Inhibit | “down-regulation of the insulin-like growth factor 1 receptor (IGF-1R)” NCT01233895 ↗ |
| Modality | Monoclonal antibody | “Anti Insulin-like Growth Factor-1 Receptor (IGF-1R/CD221) Monoclonal Antibody” NCT00774878 ↗ |
| Route | Intravenous | “administered intravenously” NCT00774878 ↗ |
| Target | IGF1R | “Anti Insulin-like Growth Factor-1 Receptor (IGF-1R/CD221) Monoclonal Antibody” NCT00774878 ↗ |